Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomesKarl S. Peggs, Anna Sureda, Wendi Qian et al.|British Journal of Haematology|2007Cited by 106
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK<i>one</i> randomized dose selection trialSteve Schey, James Cavet, Kwee Yong et al.|British Journal of Haematology|2015Cited by 20